Trial Profile

Randomized phase II study of Erlotinib vs. S-1 for non-small lung cancer after failure of two or three prior

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 18 Dec 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary) ; Gimeracil/oteracil/tegafur (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms HOT1002

Most Recent Events

01 Nov 2017 Results published in the Cancer Chemotherapy and Pharmacology
18 Oct 2017 Results comparing clinical outcomes between erlotinib and S-1 as third or fourth line therapy, presented at the 18th World Conference on Lung Cancer.
29 Mar 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com